Loading clinical trials...
Loading clinical trials...
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Conditions
Interventions
Gammaplex (5%)
Gammaplex 10
Locations
17
United States
Arizona Allergy Associates
Chandler, Arizona, United States
Miller Children's Hospital
Long Beach, California, United States
Childrens Hospital Los Angeles
Los Angeles, California, United States
UCLA Medical Center
Los Angeles, California, United States
IMMUNOe International Research Centers
Centennial, Colorado, United States
Joe DiMaggio Children's Hospital
Hollywood, Florida, United States
Start Date
February 1, 2014
Primary Completion Date
January 1, 2016
Completion Date
May 1, 2016
Last Updated
March 29, 2017
NCT02579967
NCT07284641
NCT03335605
NCT00538915
NCT03576469
NCT01289847
Lead Sponsor
Bio Products Laboratory
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions